ASCO 2022 Conference Coverage


 

ASCO 2022 Three-Year Follow-Up of Outcomes With KTE-X19 in R/R Mantle Cell Lymphoma in ZUMA-2 Trial

92 views
June 15, 2022
Comments 0
Login to view comments. Click here to Login